Columns The MS Wire - A Column by Ed Tobias MS News That Caught My Eye Last Week: Orelabrutinib, MS Stress, Selma Blair MS News That Caught My Eye Last Week: Orelabrutinib, MS Stress, Selma Blair by Ed Tobias | July 19, 2021 Share this article: Share article via email Copy article link Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial BTK inhibitors, such as orelabrutinib, are designed to selectively block the activity of an enzyme important for the activation of B-cells and microglia. Some of those cells drive the abnormal immune responses that attack the central nervous systems of people with MS. Researchers hope orelabrutinib, which is a capsule, will lower inflammation and slow progression of all MS forms. Biogen thinks the medication has enough potential to have paid $125 million to acquire marketing rights. Biogen has signed a deal with InnoCare Pharma to acquire global commercialization and licensing rights to orelabrutinib, anĀ experimental oral BTK inhibitor (BTKi) now being tested in people with relapsing-remitting multiple sclerosis (RRMS) in a Phase 2 clinical trial. Under the terms of the agreement, Biogen will have exclusive rights to the therapy in the field of MS worldwide and of certain autoimmune diseases outside of China (including Hong Kong, Macau, and Taiwan), while InnoCare will retain the rights to it for certain autoimmune diseases in China. Click here or on the headline to read the full story. *** Actively āCopingā With Daily Stress of MS Tied to Better Life Quality Well, yeah. It seems pretty obvious to me that limiting stress can improve your life, even if you’re healthy. What interests me in this small survey, however, is the coping mechanisms people used, or didn’t use. Surprising, at least to me, is that religion and substance use were the least-used methods for coping. Actively taking steps to cope with the chronic stress of multiple sclerosis (MS) ā from keeping a sense of humor to seeking emotional and tangibleĀ support ā can help to improve patientsā quality of life, a small questionnaire-based study from Poland suggests. The study, āThe Role of Stress Perception and Coping with Stress and the Quality of Life Among Multiple Sclerosis Patients,ā was published in the journal Psychology Research and Behavior Management. Click here or on the headline to read the full story. Recommended Reading July 15, 2021 News by Marisa Wexler, MS Anti-CD20 Antibodies Reduce Myelin Loss in MS Rats *** Selma Blair to Open Summit for Young Adults With Chronic, Rare Diseases Some see this as an attempt by Selma Blair to get more publicity for herself. Others think this appearance by the actress, who has been treated for MS, will help young people with chronic diseases deal with them better. What do you think? Selma Blair, the TV and film actor who is also aĀ multiple sclerosis (MS) advocate,Ā will headline next monthās second International Virtual Summit for young adults with chronic and rare disorders. Hosted by Health Advocacy Summit (HAS), theĀ Aug. 7-8 event will focus on empowerment, resources, and connection. The event is free for young adults with a chronic or rare disease, and $25 (plus handling fees) for the general public; go here to register. Click here or on the headline to read the full story. *** Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. Heās also the author of āThe Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.ā Ed and his wife split their time between the Washington, D.C. suburbs and Floridaās Gulf Coast, trying to follow the sun. Tags Biogen, BTK inhibitor, Selma Blair Comments Laurie N. Lee I think it is great that Selma Blair is becoming active for young people with chronic and rare diseases. Anyone who would criticize her activism is a toad. Public figures really can make a difference and have resources and influence to do so. Good for you, Selma! Reply Zhanna Tarasiuk I express my deep gratitude to you for your work in spreading knowledge about multiple sclerosis and the opportunity to receive the latest information in this area, for presenting complex scientific articles in an accessible language, for your concern for the future of that part of the population of countries where this information and treatment remains practically unavailable, but your articles help navigate this channel and promote it in poor countries. With great respect, your regular reader from Belarus Reply Ed Tobias Thank you very much, Zhanna. I'm very pleased that you think what I write is useful to you. I'll continue to do my best. Ed Reply Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
March 28, 2024 News by Marisa Wexler, MS Smartphone, wearable device data found reliable to monitor MS: Study
March 28, 2024 Columns by Benjamin Hofmeister Multiple sclerosis awareness is for people with MS, too
March 28, 2024 News by Lindsey Shapiro, PhD Restoring ‘lost’ pathway of neuroprotection benefits MS mice